Lunch and Learn Series - Mar 7th, 2017

Funding and Exit Strategies:
The Value of a Biotech Business

BioPharma Consortium

in collaboration with

JLabs Bay Area

When:      Tuesday, March 7, 2017 from 9:45 AM to 12:00 PM (PST)

Where:     JLABS @ SSF
                  329 Oyster Point Blvd - 3rd Floor
                  South San Francisco, CA

Register:   https://www.eventbrite.com/e/the-value-of-a-biotechnology-business-tickets-29593178995 
(For BPC's 30% discount, enter "BioConsortium" in the Promotional Code field)

Pricing:   $25 | General Public
               $35 | Onsite

Biotech companies... do you know your worth? The wise startup company plans their exit from the beginning. In order to properly leverage your exit value you need to understand the different valuation methods, how they are used and who is using them.

John Selig, Managing Partner and co-founder of Mavericks Capital, a healthcare investment bank, will guide you through the maze of sunk costs, sum of parts, comparables, Discounted Cash Flow (DTC) and Net Present Value (NPV) to help you increase negotiating leverage and make more informed funding decisions.

Join us for an informative and interactive session.

Topics Covered:

  • The different valuation methodologies and who is using them
  • Key approaches in funding for life science companies
  • Planning exit strategies and deal structuring from the outset
  • How do my expected deal terms relate to my forecast cash flows and how can I use this to make better decisions on licensing timing?

In cooperation with JLABS SSF.
Visit http://jlabs.jnjinnovation.com/locations/jlabs-ssf for more information. 

Agenda:
9:45am | Registration
10:00am | Presentation and Q&A
11:30am | Lunch and Networking
12:00 | Program close

Speakers:

John Selig | Managing Partner, Mavericks Capital
John advises life science companies on M&A, licensing and financial strategy. He speaks frequently on topics in valuation, deal term benchmarking, and strategy in the life sciences space, including the Valuation and Finance module at BIO's Executive Management Training course for BD professionals each year and the Valuation lecture at Stanford Medical School's Entrepreneurship Program. Prior to joining Maverick's, John co-led the Life Sciences Group at Woodside Capital Partners, a boutique investment bank. For the prior 12 years, he advised both Fortune 100 and VC - backed healthcare companies on transaction strategy and valuation at Strategic Decisions Group (SDG), a global management consulting firm, and Keelin Reeds Partners, a life sciences consulting firm. While at Keelin Reeds, John led a partnership and M&A deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to provide ongoing support during deal negotiations. Prior to consulting, John was an attorney with Weil, Gotshal and Manges where he focused on M&A and corporate finance. John holds a JD from Stanford Law School, where he was an Associate Editor of Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa (FINRA 24, 63, 79).

Register: https://www.eventbrite.com/e/the-value-of-a-biotechnology-business-tickets-29593178995
(For BPC's 30% discount, enter "BioConsortium" in the Promotional Code field)

Breakfast Briefing Series, Jan 26th, 2017

Who's Who in 2017: A Rocky Road for Healthcare Investments?

JLabs Bay Area

in collaboration with

BioPharma Consortium

When:      Thursday, January 26th, 2017, 8:00-10:00 AM

Where:     JLABS @ SSF
                  329 Oyster Point Blvd - 3rd Floor
                  South San Francisco, CA

Register:   https://www.eventbrite.com/e/whos-who-in-2017-a-rocky-road-for-healthcare-investments-tickets-28638979960 (For BPC's 30% discount, enter "BioConsortium" in the Promotional Code field)

Pricing:   $12 | General Public ($8.40 with discount)
                $8 | Student/Academic ($5.60 with discount)
               $25 | Onsite

Speaker Bio:
Jon Norris is a managing director for SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on direct equity co-investment and limited partnership allocations.
In addition, he has authored numerous thought leadership pieces examining the flow of capital into healthcare, including detailed analysis of venture-backed M&A and IPOs. Norris has more than thirteen years of banking experience working with life science companies and venture capital firms.
Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.
About Jon
Norris spends most of his non-banking time with his family in Los Altos, attending and coaching many youth sports. An avid baseball fan, he still plays baseball in a men's baseball league in San Jose.

Abstract:
2016 has been another wild ride, with early surprises and a bumpy start. With 2016 in the review mirror, Jon Norris takes a look at - and makes sense of - the past trends to provide an informed look into 2017.

As the 2017 investment market takes shape, what can we expect for the IPO and M&A markets? Jon will share his expertise and provide insight into:

  • How the 2016 healthcare landscape compares to previous years
  • Current and total healthcare and sector investments
  • Which Biopharma indications attracted the most funds
  • Which venture firms are most active
  • Changes in the past crossover phenomenon
  • Exits: the trends in IPOs and M&A's

At the end of this talk you should be informed as to who is investing, and the type of deals and exits that are likely to be executed in 2017.

Register:   https://www.eventbrite.com/e/whos-who-in-2017-a-rocky-road-for-healthcare-investments-tickets-28638979960 (For BPC's 30% discount, enter "BioConsortium" in the Promotional Code field)

Panel Discussion - November 30, 2016

BIOPHARMA CONSORTIUM WITH DLA PIPER PRESENTS:

Drug Pricing in 2016: Implications for Biotech, Pharma, and the Future of Healthcare

PROGRAM OVERVIEW:
Drug pricing is arguably THE industry topic of 2016.  Pharma continues to receive pushback from patient advocacy groups and governments on pricing, in some cases leading to suggestions of eliminating high priced drugs entirely from federal healthcare reimbursement programs.  Do new drugs really cost too much?  Some pharmaceutical manufacturers seem to raise prices arbitrarily and absurdly. Why?

This panel will discuss what really goes into setting a price for a new drug or biologic.   How do we reward and foster innovation in drug pricing, while maintaining affordability for patients? How do drug manufacturers provide value to the healthcare system while rewarding shareholders? How does the negative press impact investor sentiment and valuation?  What role will the growing generics and biosimilars industry hold in creating downstream solutions for affordability? When and how may the industry expect to see government regulation in pricing, not just FDA regulation in drug development?

In this panel discussion we take a closer look at drug pricing and value determination from the perspective of a diverse set of stakeholders in the healthcare ecosystem.
Discussion Outline:

  • Why does pharma/biotech pricing appear to be erratic?  How are pricing dynamics different across regions (e.g., US vs other countries)?
  • Why is pharma/biotech pricing viewed as a complex and dysfunctional web of winners versus losers (investors, drug manufacturers, payers, providers, patients/society)? What would a “healthy ecosystem” look like in the drug pricing arena?
  • What are macro level trends and potential changes (e.g., patient cost sharing, biosimilars, regulation), and what are the potential effects on pharma/biotech pricing?
  • From the perspective of payers, what conditions influence price, payment (reimbursement), value, affordability?
  • From the perspective of providers and patients, why is affordability crucial and what are some essential considerations and factors in the doctor-patient relationship when choosing to (or not to) prescribe a new medicine?
  • From the perspective of early stage entrepreneurs and investors, which factors drive product pricing and valuation over time?
  • From the perspective of pre-market to post-market biopharmaceutical companies, what are the key considerations to support product pricing and value?

DATE: November 30, 2016
LOCATION: DLA Piper | 2000 University Ave, Palo Alto, CA 94303
AGENDA:
4:00pm | Registration & Networking  
5:00pm | Panel event – Q&A
6:15pm | Networking
7 pm    | Close

PRICING:
$25 for early registration thru Fri Nov 14
$30 for pre-registration thru Mon Nov 28
$40 for walk-ins

REGISTRATION: http://BPCNov2016Event.eventzilla.net

BIOGRAPHIES (alphabetic order)
Jonathan Freudman, MD, (Panelist) has over thirty years of experience in healthcare encompassing a wide range of clinical, administrative and business challenges. He established Freudman Healthcare Consulting LLC in 2002. His clients include venture capital, medical device and other biotechnology companies. Core competencies include planning and implementation of effective
reimbursement strategies.

Previously, Dr. Freudman managed Blue Shield of California’s Medical Policy Department. His responsibilities included new technology assessment, medical policy, disease management programs and clinical guideline development. He chaired the health plan’s Pharmacy and Therapeutics committee and served on the national Blue Cross Blue Shield Association (BCBSA) Medical Policy Committee.

His career includes 16 years of the practice of general internal medicine at Kaiser Permanente Medical Center in San Rafael, California. Administrative duties at this facility included Department Chief of Internal Medicine as well as the Medical Center’s Chief of Quality. He served on the Board of Directors of the Marin County Medical Society.

Dr. Freudman is Board Certified in Internal Medicine with added qualification in Geriatrics. He is a Fellow in the American College of Physicians and is a graduate of the George Washington University School of Medicine. He is a faculty member of University of California at San Francisco (UCSF) School of Medicine. Dr. Freudman is volunteer at the San Rafael RotoCare free clinic for the indigent and serves on the clinic’s Advisory Board.

Lisa Hagerty-McMahon (Moderator) is President of Hagerty McMahon Biotech Consulting LLC, President and Chairman of the BioPharma Consortium and Business Advisor for Maverick’s Capital LLC.

She brings deep expertise in value-driven alliance & program leadership in the life sciences and biopharmaceutical industries. Her track record in alliances spans the gamut of the small biotech / large pharmaceutical relationship model as well as the complex public-private partnership arena involving multiple pharmaceutical, government and academic partners.

Successful therapeutics in her repertoire include Naglazyme (2004-5), Orencia (2005), Vibativ (2007-9), Xtandi (2012) and Avycaz (2014-15). She is currently working on a 6th late-stage product expected to launch in 2017. Lisa is also a business advisor for Maverick’s Capital and works with small biotech companies in deal sourcing and evaluation. Additionally, Lisa brings recent large pharmaceutical M&A experience, leading development teams through asset evaluation and diligence. 

She brings over a decade of consulting experience and founded Hagerty McMahon Biotech Consulting in 2009.  She spent her early career in clinical trials at the Stanford University School of Medicine, upon completion of her thesis investigating homocysteine and other risk factors for heart disease at Stanford and BS from the University of New Hampshire. Lisa is founder of the BioPharma Consortium (BPC), a life science network organization dedicated to bringing together leading-edge science, medicine and business through high-quality, extensive and collaborative networks of life sciences professionals in San Francisco and Boston.

Nina Hill, PhD, (Panelist) is currently an Executive Director of Epidemiology, HEOR and Observational Research at Relypsa, a mid-size biotech that is part of the Galenica Group. She received her PhD from the University of Washington in Health Economics and Outcomes Research (HEOR) and an MS in epidemiology.  Her career path has taken her from the Kaiser Permanente Division of Research to Genentech, where she had responsibilities for HEOR in several different therapeutic areas.  Prior to joining Relypsa she built the HEOR functions at Affymax and Medivation where she was Senior Director, HEOR and Epidemiology.

Dr. Hill is a Health Economics expert in oncology claims analyses and economic modeling and has also served as a Member of the Blue Cross Technology Evaluation Committee for Oncology Pharmacogenomics.

Kuo Tong (Panelist) is President and Founder of Quorum Consulting.
Mr. Tong is an expert in understanding and managing economic, financial, and reimbursement forces in order to influence product acceptance and utilization. His consulting engagements focus on strategic planning and implementation in early phases of product development, during clinical evaluation, and following regulatory approval. Mr. Tong has worked across a number of different clinical specialties and therapeutic categories including: hematology and oncology; solid organ and bone marrow transplantation; infectious diseases like HIV/AIDS and hepatitis; cardiovascular diagnostics and therapeutics; dermatology; orthopedic surgery; and anesthesiology/pain medicine.

Mr. Tong is an active member of numerous professional organizations and societies including: the Academy of Managed Care Pharmacy; American Public Health Association; American Society for Blood and Marrow Transplantation; American Society of Clinical Oncology; Infectious Disease Society of America; International Society for Heart and Lung Transplantation; International Society for Pharmacoeconomics and Outcomes Research; and Society for Investigative Dermatology.

Prior to founding Quorum Consulting, Mr. Tong was a senior associate with Corning HTA (now known as Covance), a Washington, DC health care consulting firm. Prior to entering the consulting field, Mr. Tong was active in clinical and health services research at the University of California at Los Angeles Neuropsychiatric Institute and the University of Pennsylvania Department of Medicine. Mr. Tong holds degrees from the University of Pennsylvania (Philadelphia, PA) and Johns Hopkins University (Baltimore, MD).

 

Breakfast Briefing Series - Oct 21, 2016

Approaching the Patient Adherence challenge in an era with higher stakes, digital enablement, and deeper patient understanding

Speaker: Jeff Hewitt, MBA
Date/Time: Friday October 21st, 2016, 8:00-10:00 AM (PST), presentation begins at 8:30 sharp
Place: Genentech, Room 42-1D
          475 East Grand Avenue
          South San Francisco, 94080  

RSVP: http://BPCOct2016Event.eventzilla.net

Pricing: Free, but online registration is required by October 18th, 2016

Speaker Bio: 

Jeff Hewitt is a partner in the Health Practice of A.T. Kearney where he focuses upon helping life sciences companies make significant transformations, improve decision-making, and invest strategically.  This includes assisting over a dozen major life sciences companies improve their R&D decision-making and innovation capabilities through major transformations of process, governance, analytics, and culture.  Engagements have included development investment capability building, cross-therapeutic area strategy, pipeline assessments, external assessments of value, and cost-saving clinical trial optimization.  

Over twenty years he has supported well more than 100 client engagements across a variety of strategic topics such as franchise strategy, drug development, Healthcare Reform, US market pricing strategy, and patient adherence solutions.  He has a B.A. in Economics and English from Amherst College and an M.B.A from Stanford University.  He is based in A.T. Kearney’s San Francisco office.


Abstract:
The patient adherence challenge isn’t new.  Healthcare providers, pharmacists, and pharmaceutical companies have been trying to get patients to take their medicines for decades.  However, it’s different today.  Why is it different?  Life-saving specialty medicines come with high prices and high expectations, a broad collection of digital enabled tools and technologies are available, and our understanding of why patients don’t adhere has improved significantly.  These changes create the opportunity for the industry to do better.  This talk will address:

  • The changes that suggest the Patient Adherence challenge should be viewed differently today

  • The reasons that patients don’t adhere

  • What we can learn from adherence solutions in the market today

  • A framework for designing adherence solutions

  • An argument for why building this capability is valuable

Register here:  http://BPCOct2016Event.eventzilla.net
Contact: http://www.biopharmaconsortium.com/contact/

BioPharma Consortium Presents…

2016 Fall Kickoff Mixer

 

Kick off the fall season in style with the BioPharma Consortium!

When:      Wednesday, September 21, 2016, 6:00-8:30 PM
Where:      Porterhouse Restaurant
                  60 E. Third Ave
                  San Mateo, CA
Pricing:    $20, if pre-registered by noon, Friday September 16
                 $30 walk-in (cash only)
Register:   http://BPC2016FallKickoff.eventzilla.net

Are you ready for the final quarter of the year? What’s lingering on your professional bucket list for 2016? Looking for new opportunities, new leads, recruiting resources or ramping up your own professional development?

If it’s leading edge in biotech and life sciences, we’re talking about it at BPC. Don’t miss our lineup of programs in the coming months…..small biotech asset valuation for out-licensing (how NOT to get taken to the cleaners in this multi-year wave of deals and dollars?)…..drug pricing amid unprecedented public scrutiny and government pressure (is there a win-win-win path among patients, payers and pharma?)…..patient user experience & understanding adherence in the context of digital health.....disruptive digital health products and how is the FDA responding when high tech meets biotech? 

Come talk it up with us!  Come talk it up with our partners! 
We’ll see you in the bar & lounge over drinks & appetizers.  Cash bar.

-The "Crew" at BPC

Contact:    http://www.biopharmaconsortium.com/contact/
Register:   http://BPC2016FallKickoff.eventzilla.net

Breakfast Briefing Series - May 20th, 2016

Must-Know Finance Concepts for Life Sciences Valuations:  Good, Bad, & Most Effective

Speaker: John Selig, Co-Founder and Managing Partner, Mavericks Capital
Date/Time: Friday May 20th, 2016, 8:00-10:00 AM (PST), presentation begins at 8:30 sharp
Place: Genentech, Room 42-1E
          475 East Grand Avenue
          South San Francisco, 94080  

RSVP: http://bpcmay2016event.eventzilla.net

Pricing: Free, but online registration is required by May 18, 2016

Speaker Bio:

John advises life sciences companies on M&A, licensing and financial strategy and speaks frequently on topics in valuation, deal term benchmarking, and strategy. Additionally, he teaches the Valuation and Finance module at BIO’s Executive Management Training course for BD professionals each year, and he will be teaching the Valuation module at Stanford Medical School’s Entrepreneurship Program.

Prior to joining Mavericks, John was a Managing Director at Woodside Capital Partners, a boutique investment bank. Previously, he was a management consultant, first at Strategic Decisions Group and later at Keelin Reeds Partners, where he advised both top 20 pharma and medtech companies as well as dozens of VC-backed and small- to mid-cap life sciences companies on M&A, licensing strategies, portfolio management, valuation and strategic direction. John has extensive experience in applying licensing and M&A data to inform product strategy and provide ongoing support during deal negotiations, which has yielded market-value deal terms for dozens of assets. John also combined his expertise in valuation, deal term benchmarking and decision analysis with his background in law to help companies make optimal decisions in litigation and settlement.

Prior to consulting, John was an attorney with Weil, Gotshal and Manges LLP, where he focused on M&A and corporate finance. John holds a JD from Stanford Law School, where he was an Associate Editor of the Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa. (FINRA 24, 63, 79)

Abstract:
This talk will present an introduction to the key concepts and most common methodologies used to evaluate life sciences assets.

If you are an entrepreneur interested in raising financing, licensing an asset or selling your company; a private investor who wants to estimate and negotiate start-up share value; or any other professional who is active in the investing sector, you'll benefit from this overview of the key concepts used in life sciences valuation discussions.

Portfolio and program managers who iteratively perform valuation of their assets in mid to late stages of drug development will also benefit from this talk.

Topics covered include:
•    The various valuation methodologies used to assign a value to life science businesses and assets
•    The methodologies used in particular by pharma partners and venture capitalists
•    An explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital and present value
 

Register here:  http://bpcmay2016event.eventzilla.net
Contact: http://www.biopharmaconsortium.com/contact/

Lunch-and-Learn Series - Apr 22, 2016

How to Develop a Winning Patent Portfolio

Speakers: John Storella, Intellectual Property Law For Innovators In Biotechnology
                  Shirley Recipon, Life Science and Intellectual Property Professional
Date/Time: Friday, April 22, 2016, 11:30 AM - 1:30 PM
                   Networking lunch: 11:30 AM
                   Seminar: 12:00: PM
                   Networking & Questions: 1:00 PM
Place: Molecular Medicine Research Institute
           428 Oakmead Pkwy
           Sunnyvale, CA 94085

RSVPhttp://bpcapril2016event.eventzilla.net

Pricing: Free, but pre-registration is required

Speaker Bios:
John Storella advises early stage biotechnology companies about developing and executing intellectual property strategies.  In a career spanning more than 25 years, John has worked at Fish & Neave (now Ropes & Gray), Townsend and Townsend (now Townsend Kilpatrick), Ciphergen Biosystems and Wilson Sonsini.  He currently practices from his own offices in Berkeley.  His clients have included Biogen, Eli Lilly, Regeneron, Affymetrix, University of California, Geron, Counsyl, Pathwork Diagnostics, Cellerant Therapeutics, IntegenX, Ajinomoto Althea and Guardant Health. 

Shirley Recipon applies her over 15 years experience as a Patent Agent in delivering US and foreign patent preparation and prosecution, strategic patent counseling and efficient IP portfolio management.  She enjoys seamlessly merging her scientific knowledge, including research at Johns Hopkins and the NIH, to protect and advance a company’s IP position. Her experience includes supporting innovators and business goals and objectives at Incyte, Applied Biosystems, Life Technologies and DuPont

Abstract:Building a patent portfolio is much more than filing patent applications on your inventions.  At its best, a patent strategy coordinates technology development with corporate strategy, market opportunity and competitor analysis.  A strong patent portfolio gives a company a competitive advantage by creating a zone of exclusion for the valuable features of your product. Patents also protect your freedom to operate by providing defensive and offensive assets against those who would assert their patents against you.  A well conceived patent strategy makes your company attractive to investors.  They also can be monetized through licensing opportunities.

Register here:  http://bpcapril2016event.eventzilla.net
Contact: http://www.biopharmaconsortium.com/contact/

January 27

BioPharma Consortium Presents…

2016 New Year Mixer

 

Come Celebrate the New Year in Style with the BioPharma Consortium!

What's reigning in the talk of 2016?  A year ahead of VC growth....doubling down on drug pricing pressures....growing centers of innovation.....globalization and regulatory implications.....more M&A?

In the coming months, keep an eye out for leading-edge programming at BPC.

Catch the latest biotech beat over drinks & apps and expand your network!
We look forward to seeing you soon, 
The "Crew" at BPC

When:      Wednesday, January 27, 2016, 6:00-8:30 PM

Where:      Porterhouse Restaurant
                  60 E. Third Ave
                  San Mateo, CA

Pricing:    $20, if pre-registered by January 20
                 $25 extended online registration January 21 - January 26
                 $30 walk-in (cash only)

Register Here: http://www.eventzilla.net/web/event/january-27th-biopharma-consortium--new-year-mixer-2138839429

Join us in the bar and lounge for an evening of delicious appetizers and free-flowing networking.  Cash bar. 

Enjoy a relaxed evening out socializing and catching up on the latest industry buzz with your fellow professionals in biotech.

Contact:    http://www.biopharmaconsortium.com/contact/

Breakfast Briefing Series - Dec 2, 2015

Who's Who in 2015: Exploring the Exciting BioPharma Venture Ride

Speaker: Jonathan Norris | Managing Director, Silicon Valley Bank
Date/Time: Wednesday, December 2nd, 8:00-10:00 AM, presentation begins at 8:30 sharp
Place: Johnson & Johnson Innovation, JLABS
           329 Oyster Point Blvd – 3rd Floor
           South San Francisco, CA

RSVP: https://www.eventbrite.com/e/whos-who-in-2015-exploring-the-exciting-biopharma-venture-ride-tickets-19168529588

Pricing: $12 | General Public
            $8 | Student/Academic
            $25 | Onsite

Speaker Bio:
Jon Norris is a managing director for SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on direct equity co-investment and limited partnership allocations. In addition, he has authored numerous thought leadership pieces examining the flow of capital into healthcare, including detailed analysis of venture-backed M&A and IPOs. Norris has more than thirteen years of banking experience working with life science companies and venture capital firms. Prior to joining SVB Capital, Norris was a founding member and senior vice president of Square 1 Bank, an early stage technology bank, where he was responsible for sourcing deals and managing regional and national venture capital relationships. Norris also served more than six years at Imperial Bank (subsequently acquired by Comerica Bank), most recently as senior vice president and group manager of the Northern California Life Science Practice. Prior to banking, Norris was a practicing litigation attorney, specializing in employment defense and toxic tort litigation. Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University. 

About John: Norris spends most of his non-banking time with his family in Los Altos, attending and coaching many youth sports. An avid baseball fan, he still plays baseball in a men's baseball league in San Jose. 

Abstract:
2015 has been a wild ride, but how does it compare to 2013 and 2014? What does it take to go IPO and when are acquirers engaging in M&A? This presentation will explore the current state of the BioPharma venture world and include the following topics: 

    • What does it take to go IPO and when are acquirers engaging in M&A? 
    • Explore current equity financings vs. the last three years
    • Analysis of which venture firms are most active
    • The crossover phenomenon and what does it mean for your company? 
         - Which crossovers are investing and at which stage
         - Step-up in private equity rounds
         - IPO pre-money valuation and IPO success
    • Exits: the trend to early stage M&A in Biopharma, and explore time to exit, up front and all-in values, and                           multiples on capital invested by indication. 
    • IPOs:
         - Types of IPOs completed since 2013 and changes in 2015 to date
         - Average dollars raised and pre money by indication.

At the end of this talk you should be informed as to who is investing in BioPharma and comps for M&A and IPO in your indication. 

Register here:  https://www.eventbrite.com/e/whos-who-in-2015-exploring-the-exciting-biopharma-venture-ride-tickets-19168529588
Contact: http://www.biopharmaconsortium.com/contact/

BPC Partner Event - FrenchBioBay Holiday Surpise

HOLIDAY SURPRISE
An evening of mutual discovery
Hosted by MMRI and French Bio Bay
in partnership with
The Biopharma Consortium

Date/Time: Wednesday, December 2nd, 6:00-9:00 PM
Place: MMRI
            Molecular Medicine Research Institute
            428 Oakmead Parkway
            Sunnyvale, CA 94085

Cover: 25$ in advance, 40$ at the door

RSVP: http://fbb-holiday-surprise.eventzilla.net
Registrations will be closing on 11/30

Come and discover MMRI, an incubator muy sympatico, filled with people of the same breed

Meet the teams
Visit the MMRI labs, hear the stories from the entrepreneur's own mouth
What makes MMRI so special is the focus it places on technology. This is not an incubator where people think that sharing a copy machine is essential. Rather, the founders understand that until a startup has the ability to do a decent proof of concept, nothing will really move from a funding standpoint. So MMRI focuses on providing an optimal technological environment to its members. The labs are superbly equipped , MMRI is one of the few incubators with a vet and animals on site.
We will organize visits of the labs for those that are interested.
Here is a list of the teams that you will be able to meet:

Amarit Biosciences
Caligenics
Clearlight Diagnostics
Dermira
Epiphany
Farad Power
Flora Bioscience
Geofossil Fuels
Gliaglogix
Lundry, LLC
Plaxgen
Riboscience
Translational Bioscience
TranscripTx
Transporin

 

Mingle and have fun
Animations, roundtables, holiday cheers
Help us design an original event by deciding what format you would like for this holiday mingle and peer networking.
We could do some roundrobin incubator tours, roundtables and discussions groups with topics of interest and, of course, some good food and drinks.
You decide!
Send us your suggestions, topics and ideas for the event at frenchbiobay@gmail.com or enter the discussion on our LinkedIn group (http://www.linkedin.com/groups?about=&gid=31811) or Facebook page (https://www.facebook.com/groups/226136047451773/).

RSVP: http://fbb-holiday-surprise.eventzilla.net
Registrations will be closing on 11/30

Breakfast Briefing Series - Nov 6, 2015

Better, faster, cheaper – the future of US healthcare?

Speaker: Mike Spencer
Date/Time: Friday, November 6th, 8:00-10:00 AM, presentation begins at 8:30 sharp
Place: Genentech, 42-1D in Bldg 42
           475 East Grand Avenue
           South San Francisco 94080

RSVP: http://bpcnov2015.eventzilla.net
(Admission is free, but registration is required by 10:00 AM 11/4)

Speaker Bio:
Mike Spencer is the Administrative Director of the Performance Improvement department at Stanford Children’s Health (SCH) & Lucile Packard Children’s Hospital (LPCH). At SHC and LPCH, the PI department facilitates SCH’s transformation to a lean management system – with a true north vision of providing “nurturing care, extraordinary outcomes for healthier, happy lives”. 

Mike joined Stanford in 2011 coming from Bay Area biotech pioneer Genentech where he was both Director of Business Integration Management and Director of Project Management in Development Sciences from 2003 - 2010. Prior to his roles at Genentech, Mike held multiple leadership roles in supply chain management, management consulting, and project management.

Mike brings to SCH/LPCH a broad set of skills garnered from careers across multiple industries & multiple functions. He considers himself a generalist whose skills complement the scientific & medical experts in outstanding organizations such as Stanford, Genentech & Raychem.

Two common threads run through Mike’s roles: continuous improvement through collaboration, and building sustainable organizational capabilities.

Formative experiences include his current role as change agent for lean in healthcare; extending project management capability within scientific groups in biotechnology; improving quality and delivery times in multinational high-tech manufacturing.

Abstract:
US healthcare costs consistently rank as the most expensive in the world, with outcomes & satisfaction far down the ranking.

Many hospitals & healthcare systems are aggressively implementing lean management systems, to sustainably eliminate waste, improve care & increase patient satisfaction. Lean principles, directly based on decades of experience in manufacturing & other industries, have been proven to complement both the science & the art of medicine.

What if we could reduce total drug development time by 20 or 30%? The resultant benefits would be huge - to society in getting drugs to patients faster, & to biopharma in reversing the otherwise inexorable increases in costs.

By examining micro-level lean improvement in healthcare, we can explore the impact on macro-drug development processes.

Register early, you won't want to miss this!

Contact:http://www.biopharmaconsortium.com/contact/

Panel Discussion

The Association of Strategic Alliance Professionals
Presents in Colloboration with the
BioPharma Consortium

Transforming Healthcare through Strategic Partnerships
Hi Tech Meets Bio Tech


Date/Time: Wednesday, October 14, 2015, 5:30-8:00 pm
Place: Salesforce.com
           50 Freemont Street
           Fourth Floor
           San Francisco, CA
RSVP: www.strategic-alliances.org
Pricing: ASAP Members - $20
          BioPharma Consortium Members –$30
          with promo code: sv714biopharmcon
          Non-Members - $45+ $10 at the door

 

Featuring our Panel of Distinguished Experts
Lisa Hagerty-McMahon, President, Hagerty-McMahon Biotech Consulting and the BioPharma Consortium
Michael A. Goldman, Ph.D. Professor & Chair SF State Department of Biology
Josephine Harada, Associate Director of Alliances, Illumina, Inc. 
Alan Lindsay, Senior Director, Healthcare & Life Sciences Industry Alliances, Salesforce.com
Dave Schulte, Healthcare Venture Capital, McKesson Ventures

Register early, you won't want to miss this!

Contact: Norma Watenpaugh
              normaw@phoenixcg.com

2015 Fall Fling Mixer - Oct 1

BioPharma Consortium and French BioBay Present…

2015 Fall Fling Mixer

 

It’s not too late to expand your network in 2015…Make new professional connections and deepen existing ones!

When:      Thursday, October 1, 2015, 6:00-8:30 PM

Where:      Porterhouse Restaurant
                  60 E. Third Ave
                  San Mateo, CA

Pricing:    $20, if pre-registered by Sunday, September 27
                 
$30 walk-in (cash only)

Register:    http://bpcoct2015.eventzilla.net/

Join us in the bar and lounge for an evening of delicious appetizers and free-flowing networking.  Cash bar. 

Enjoy a relaxed evening out socializing and catching up on the latest industry buzz with your fellow professionals in biotech.

Contact:    http://www.biopharmaconsortium.com/contact/

Breakfast Briefing Series - May 29, 2015

Looking Forward by Glancing Back: A Review of the Current Biopharma Deals Landscape with Emerging Trends in Licensing and M&A

Speaker: Laura Vitez, Principal Business Analyst, Thomson Reuters
Date/Time: Friday, May 29th, 8:00-10:00 AM, presentation begins at 8:30 sharp
Place: Novartis Pharmaceuticals Corporation 201 Industrial Road
(2nd floor lobby, Navier-Stokes conference rooms)
San Carlos, CA 94070

RSVP: http://bpcmay2015.eventzilla.net/
(Admission is free, but registration is required by 10:00 AM 5/27)

Speaker Bio:

Laura Vitez is the Principal Business Analyst for Thomson Reuters working with life science firms to identify and execute an optimized business development strategy. Since 2003 she has been serving as a consultant to the senior teams of top-tier small and mid-sized biotech companies in the San Francisco and San Diego areas.
Laura has participated in alliances generating more than $2 billion in value for her clients and companies. These include the acquisitions of Intellikine by Takeda/Millennium, and of Rinat by Pfizer; profit sharing agreements including Intellikine with Infinity/Purdue, KaloBios with Sanofi-Pasteur, and Rinat with Genentech; and multiple other arrangements including Maxygen with Codexis, Signature with MDS Sciex, Schwarz with Aryx, and various licenses and partnerships for Cell Genesys.
Prior to launching her consulting practice Laura led the early business development efforts of Signature Biosciences, a technology firm developing microwave spectroscopy-based instrumentation; ran west coast business development operations for Schwarz Pharma, a mid-size German pharmaceutical company; held a managing director role at the merchant banking arm of Burrill & Company; and was the twelfth employee at Cell Genesys, working on business development of their cell and gene therapy programs.
Laura began her career at the bench, working in labs at Somatogen Inc., National Jewish Center for Immunology and Respiratory Medicine, Northwestern University, and Indiana University. She holds a BA in mathematics and chemistry and an MS in Biochemistry, Molecular and Cellular Biology, and completed a business series at University of California at Berkeley.

Abstract:
Recent trends in life sciences deal-making based on Thomson Reuters Recap data will be presented. In addition, a detailed analysis of emerging trends in licensing and M&A over the last 12 months will be provided, including:
-Key financial metrics
-Most active dealmakers
-Trends by therapeutic area
-A showcase of the largest deals signed in 2014

Register early, you won't want to miss this!